1. Gonadotropin-releasing hormone (GnRH) is released from the hypothalamus and binds its receptor on anterior pituitary gonadotroph cells. Which of the following best describes the GnRH receptor and its primary downstream signaling mechanism?
A) A ligand-gated ion channel that allows calcium influx directly into the gonadotroph cell upon GnRH binding
B) A Gs-coupled G protein-coupled receptor (GPCR) that activates adenylyl cyclase and raises intracellular cyclic AMP
C) A Gq-coupled G protein-coupled receptor (GPCR) that activates phospholipase C beta, generating IP3 and DAG and mobilizing intracellular calcium to stimulate LH and FSH secretion
D) A receptor tyrosine kinase that undergoes autophosphorylation and activates the MAP kinase cascade to drive gonadotropin gene transcription
E) A Gi-coupled G protein-coupled receptor (GPCR) that inhibits adenylyl cyclase and reduces intracellular cAMP to suppress tonic gonadotropin release
ANSWER: C
Rationale:
This question asked you to identify the receptor type and signaling pathway used by GnRH at the anterior pituitary. The GnRH receptor (GnRHR) is a Gq-coupled GPCR. Gq activation stimulates phospholipase C beta (PLC-beta), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers intracellular calcium release from the endoplasmic reticulum, and DAG activates protein kinase C; together these second messengers drive exocytosis of LH and FSH and stimulate gonadotropin subunit gene transcription.
Option A: Option A is incorrect because GnRHR is not a ligand-gated ion channel; it is a seven-transmembrane GPCR with no intrinsic ion-channel function.
Option B: Option B is incorrect because Gs-coupled receptors activate adenylyl cyclase and raise cAMP — this is the signaling pathway used by GHRH and CRH receptors, not GnRHR.
Option D: Option D is incorrect because receptor tyrosine kinases are used by growth factors such as insulin and EGF; GnRHR belongs to the GPCR superfamily and does not possess intrinsic kinase activity.
Option E: Option E is incorrect because Gi-coupled receptors inhibit adenylyl cyclase and suppress intracellular cAMP — this is the signaling pathway used by somatostatin receptors (SSTR1–5), not the stimulatory GnRHR.
2. A 28-year-old woman with hypothalamic amenorrhea due to absent endogenous GnRH pulses is treated with exogenous GnRH delivered by a pulsatile pump set to release one pulse every 60 to 90 minutes. A different patient with estrogen receptor-positive breast cancer is treated with a once-monthly depot injection of leuprolide, a GnRH agonist. Which of the following best explains why the same drug class produces opposite gonadotropin effects in these two clinical contexts?
A) Pulsatile GnRH stimulates LH and FSH release by repeatedly activating and allowing GnRH receptor recovery, while continuous GnRH agonist exposure causes receptor downregulation and desensitization, suppressing gonadotropin secretion
B) Pulsatile GnRH activates Gs-coupled signaling to raise cAMP, while continuous agonist exposure shifts receptor coupling to Gi, which inhibits adenylyl cyclase and reduces gonadotropin release
C) The pulsatile pump delivers GnRH directly to pituitary portal blood, bypassing hepatic first-pass metabolism, while the depot injection undergoes hepatic extraction that converts leuprolide into an active antagonist metabolite
D) Pulsatile GnRH selectively stimulates FSH without affecting LH, maintaining the FSH-to-LH ratio needed for folliculogenesis, while continuous exposure preferentially suppresses LH, eliminating the mid-cycle LH surge
E) The pulsatile pump uses native GnRH which has high receptor affinity, while leuprolide has lower receptor affinity and requires prolonged occupancy to achieve the same signaling amplitude, eventually depleting downstream second messenger pools
ANSWER: A
Rationale:
This question asked you to explain the pharmacodynamic basis for pulsatile stimulation versus continuous suppression by GnRH agonists. Endogenous GnRH is secreted in discrete pulses approximately every 60 to 90 minutes; each pulse binds GnRHR, activates Gq signaling, triggers LH and FSH release, and then dissociates — allowing the receptor to recover before the next pulse. Continuous GnRH receptor occupancy (as with a depot GnRH agonist) causes receptor downregulation through internalization and uncoupling, ultimately eliminating gonadotropin secretion. This pulsatility-dependent regulation is the pharmacological basis for using GnRH agonists as medical castration agents in oncology.
Option B: Option B is incorrect because GnRHR does not switch its G protein coupling from Gs to Gi with continuous exposure; the suppression is due to receptor downregulation and desensitization, not a change in G protein subtype.
Option C: Option C is incorrect because the route of administration and hepatic metabolism do not convert a GnRH agonist into an antagonist; leuprolide remains an agonist regardless of formulation, and its suppressive effect is due to the pharmacodynamic consequence of continuous receptor activation, not a metabolic transformation.
Option D: Option D is incorrect because pulsatile GnRH stimulates both LH and FSH — GnRH does not selectively stimulate one gonadotropin; the relative LH-to-FSH ratio is influenced by pulse frequency, not by whether stimulation is pulsatile versus continuous in a binary sense.
Option E: Option E is incorrect because leuprolide actually has higher receptor affinity and resistance to degradation compared with native GnRH (due to D-amino acid substitutions), which is precisely why it produces more prolonged and potent receptor activation leading to downregulation — the effect is not due to lower affinity or second messenger depletion.
3. Thyrotropin-releasing hormone (TRH) is synthesized in the paraventricular nucleus of the hypothalamus and released into portal blood to act on anterior pituitary thyrotroph cells. Which of the following correctly describes the structure of TRH and the receptor through which it acts?
A) TRH is a 41-amino-acid peptide that acts through a Gs-coupled GPCR, raising intracellular cAMP to stimulate TSH gene transcription and secretion
B) TRH is a 10-amino-acid nonapeptide stored in Herring bodies of the posterior pituitary and released directly into the systemic circulation upon hypothalamic stimulation
C) TRH is a 44-amino-acid peptide that acts through a receptor tyrosine kinase on thyrotroph cells, activating the JAK-STAT pathway to drive TSH subunit gene expression
D) TRH is a tripeptide (pyroGlu-His-Pro-NH2) that acts through a Gq-coupled GPCR, activating phospholipase C beta to generate IP3 and DAG, mobilizing intracellular calcium to trigger TSH secretion
E) TRH is a steroid hormone synthesized de novo in hypothalamic neurons from cholesterol precursors and acts through a nuclear receptor to regulate TSH gene transcription over hours to days
ANSWER: D
Rationale:
This question asked you to identify the structure of TRH and its receptor class. TRH is a tripeptide with the sequence pyroGlu-His-Pro-NH2 — it is one of the simplest hypothalamic hormones in terms of primary structure. The TRH receptor (TRHR) is a Gq-coupled GPCR; like the GnRH receptor, its activation drives PLC-beta-IP3-DAG signaling with intracellular calcium mobilization, triggering both TSH exocytosis and TSH alpha and beta subunit gene transcription.
Option A: Option A is incorrect because TRH is not a 41-amino-acid peptide — that description applies to corticotropin-releasing hormone (CRH); additionally, TRHR is Gq-coupled, not Gs-coupled (the Gs-cAMP pathway is used by CRH-R1 and GHRH receptors).
Option B: Option B is incorrect because TRH is synthesized in the hypothalamus and released into portal blood to reach anterior pituitary thyrotrophs; Herring bodies are storage granules in the posterior pituitary for oxytocin and vasopressin, which are nonapeptides — TRH is unrelated to the posterior pituitary.
Option C: Option C is incorrect because TRH is not a 44-amino-acid peptide (that describes GHRH) and does not act through a receptor tyrosine kinase or JAK-STAT pathway; it is a GPCR ligand.
Option E: Option E is incorrect because TRH is a peptide, not a steroid; steroid hormones are lipid-derived and act at nuclear receptors, whereas TRH is a hydrophilic tripeptide that acts at a membrane-bound GPCR with rapid (minutes) rather than genomic (hours) primary signaling.
4. A 34-year-old woman presents with secondary amenorrhea, galactorrhea, and an elevated serum prolactin level. Thyroid function tests reveal a markedly elevated TSH and low free T4, consistent with severe primary hypothyroidism. No pituitary tumor is identified on MRI. Which of the following best explains the mechanism by which hypothyroidism produces hyperprolactinemia in this patient?
A) Low circulating T4 reduces negative feedback at the hypothalamus, causing increased dopamine secretion from TIDA neurons, which paradoxically stimulates lactotroph cells through an incompletely understood off-target effect
B) Chronically elevated TRH, driven by absent thyroid hormone negative feedback, stimulates TRH receptors on anterior pituitary lactotroph cells as well as thyrotroph cells, directly stimulating prolactin secretion
C) Primary hypothyroidism causes pituitary enlargement with mass effect on the lactotroph cell population, compressing the portal circulation and reducing dopamine delivery to prolactin-secreting cells
D) Low T4 levels directly bind lactotroph cell nuclear receptors and upregulate the prolactin gene promoter, independent of any hypothalamic hormone input
E) Elevated TSH cross-reacts with the prolactin receptor at pharmacologically relevant concentrations, acting as a partial agonist to stimulate prolactin secretion from lactotroph cells
ANSWER: B
Rationale:
This question asked you to identify why primary hypothyroidism can cause hyperprolactinemia. When circulating thyroid hormone levels fall, negative feedback on the hypothalamus is lost, driving chronically elevated TRH secretion into the portal circulation. The TRH receptor is expressed not only on thyrotroph cells but also on lactotroph cells, and TRH is a direct stimulator of prolactin secretion through the same Gq-PLC-IP3-DAG pathway. Prolonged TRH hypersecretion in untreated hypothyroidism therefore produces hyperprolactinemia — a clinically important cause of galactorrhea and amenorrhea that resolves with adequate levothyroxine replacement.
Option A: Option A is incorrect because TRH-driven hyperprolactinemia does not involve increased dopamine; in fact, dopamine is the primary inhibitor of prolactin, and elevated TRH acts by directly stimulating lactotrophs, not by altering TIDA pathway activity.
Option C: Option C is incorrect because while a chronically stimulated pituitary in primary hypothyroidism can enlarge (thyrotroph hyperplasia), this is not the primary mechanism for hyperprolactinemia in this condition; the direct TRH stimulation of lactotrophs is the correct explanation.
Option D: Option D is incorrect because low T4 levels do not directly bind lactotroph nuclear receptors to upregulate prolactin; thyroid hormone receptors are predominantly expressed in tissues where T3/T4 regulate metabolism and development, and the prolactin-stimulating effect is mediated via TRH, not direct thyroid hormone receptor action on lactotrophs.
Option E: Option E is incorrect because TSH does not cross-react with the prolactin receptor at physiologically or pharmacologically relevant concentrations; TSH and prolactin are structurally distinct glycoprotein hormones acting through different receptors.
5. Corticotropin-releasing hormone (CRH) is a 41-amino-acid peptide released from the paraventricular nucleus into portal blood to stimulate ACTH secretion from pituitary corticotroph cells. Which of the following correctly identifies the receptor subtype primarily responsible for pituitary ACTH release and its G protein coupling?
A) CRH receptor type 2 (CRH-R2), which is Gq-coupled and activates phospholipase C to mobilize intracellular calcium and drive ACTH exocytosis from corticotroph cells
B) CRH receptor type 1 (CRH-R1), which is Gi-coupled and inhibits adenylyl cyclase, reducing cAMP to disinhibit POMC gene transcription and ACTH secretion
C) A non-selective CRH receptor shared equally between CRH-R1 and CRH-R2, both of which are Gq-coupled and act synergistically to produce the full pituitary ACTH response
D) CRH receptor type 2 (CRH-R2), which is Gs-coupled, predominantly expressed on pituitary corticotroph cells, and is the primary driver of POMC gene transcription and ACTH secretion
E) CRH receptor type 1 (CRH-R1), which is Gs-coupled and activates adenylyl cyclase, raising intracellular cAMP and activating protein kinase A to stimulate POMC gene transcription and ACTH secretion
ANSWER: E
Rationale:
This question asked you to identify which CRH receptor subtype drives pituitary ACTH release and how it signals. CRH-R1 is the dominant receptor on pituitary corticotroph cells and is the primary mediator of ACTH secretion in response to hypothalamic CRH. CRH-R1 is Gs-coupled: Gs activates adenylyl cyclase, raises intracellular cAMP, and activates protein kinase A (PKA), which in turn stimulates pro-opiomelanocortin (POMC) gene transcription and ACTH exocytosis. This Gs-cAMP-PKA pathway is shared with the GHRH receptor and is distinct from the Gq-PLC-IP3 pathway used by GnRHR and TRHR.
Option A: Option A is incorrect because CRH-R2, not CRH-R1, is the receptor with broader peripheral expression (heart, skeletal muscle, brain), and importantly CRH receptors are Gs-coupled, not Gq-coupled — the Gq-IP3-calcium pathway applies to GnRHR and TRHR, not CRH receptors.
Option B: Option B is incorrect because CRH-R1 is Gs-coupled and stimulatory, not Gi-coupled and inhibitory; Gi coupling with cAMP reduction describes somatostatin receptors.
Option C: Option C is incorrect because CRH-R1 and CRH-R2 have distinct expression patterns and functions — CRH-R1 predominates at the pituitary for ACTH release, while CRH-R2 is expressed mainly in peripheral tissues; they are not interchangeable or synergistic in this context, and neither is Gq-coupled.
Option D: Option D is incorrect because it correctly identifies Gs coupling but misassigns the subtype — CRH-R2, not CRH-R1, is described; CRH-R1 is the pituitary-dominant receptor that drives ACTH secretion.
6. A patient with acromegaly caused by a growth hormone-secreting pituitary adenoma is started on a somatostatin analog. The prescribing clinician chooses octreotide rather than pasireotide. Which of the following best describes the somatostatin receptor subtype selectivity that distinguishes octreotide from pasireotide, and how this selectivity affects clinical utility?
A) Octreotide and lanreotide selectively target somatostatin receptor subtypes 2 and 5 (SSTR2/SSTR5), which predominate on most GH-secreting pituitary adenomas, while pasireotide is a pan-receptor agonist with high affinity for SSTR1, SSTR2, SSTR3, and SSTR5, providing superior control in SSTR2-poor tumors but with substantially higher rates of hyperglycemia
B) Octreotide selectively targets SSTR1 and SSTR4, which are expressed predominantly in the brain and peripheral tissues, while pasireotide targets only SSTR2 and SSTR5 on pituitary somatotroph cells, making pasireotide the preferred first-line agent for acromegaly
C) Octreotide is a pan-receptor agonist that activates all five SSTR subtypes with equal affinity, while pasireotide selectively blocks SSTR3-mediated pro-apoptotic signaling to reduce tumor cell death in GH-secreting adenomas
D) Both octreotide and pasireotide are selective for SSTR2 only, but pasireotide has a longer plasma half-life due to PLGA depot formulation, which is the primary reason it is reserved for cases where octreotide fails to control GH levels
E) Octreotide is an SSTR antagonist that competitively blocks somatostatin binding and prevents receptor internalization, extending receptor surface expression, while pasireotide is a full agonist that causes rapid receptor desensitization
ANSWER: A
Rationale:
This question asked you to distinguish octreotide from pasireotide based on somatostatin receptor subtype selectivity. Octreotide and lanreotide are SSTR2/SSTR5-selective agents; SSTR2 predominates on most GH-secreting pituitary adenomas (somatotrophinomas), making these agents effective in most patients with acromegaly. Pasireotide is a pan-SSTR agonist with high affinity for SSTR1, SSTR2, SSTR3, and SSTR5; it achieves superior GH and IGF-1 suppression in tumors with low SSTR2 expression but high SSTR5 expression, and in Cushing disease (pituitary corticotrophs express SSTR5 more than SSTR2). However, pasireotide's potent SSTR5 agonism on pancreatic beta cells suppresses insulin secretion, producing hyperglycemia in approximately 73% of patients — substantially more than the 20 to 30% incidence with octreotide or lanreotide.
Option B: Option B is incorrect because octreotide does not target SSTR1 and SSTR4; it targets SSTR2 and SSTR5, while SSTR1 and SSTR4 are expressed in brain and peripheral tissues but are not the primary mediators of GH suppression — this description reverses the pharmacology.
Option C: Option C is incorrect because octreotide is not a pan-receptor agonist; it is SSTR2/SSTR5-selective, and pasireotide does not selectively block SSTR3-mediated apoptosis — pasireotide is a pan-agonist, not an SSTR3 antagonist.
Option D: Option D is incorrect because octreotide and pasireotide are not both selective for SSTR2 only; their receptor selectivity profiles differ substantially as described above, and the reason pasireotide is not first-line is its hyperglycemia risk and cost, not simply a half-life difference.
Option E: Option E is incorrect because octreotide is a somatostatin receptor agonist, not an antagonist; it mimics somatostatin by activating SSTR2 and SSTR5 to suppress GH secretion.
7. Prolactin is unique among the major anterior pituitary hormones in that its secretion is under predominant inhibitory rather than stimulatory hypothalamic control. Which of the following correctly identifies the hypothalamic pathway responsible for this tonic inhibition and the receptor through which it acts at the pituitary?
A) Somatostatinergic neurons in the periventricular nucleus project to the median eminence and release somatostatin into portal blood, where it binds SSTR2 receptors on lactotroph cells to suppress prolactin secretion via Gi-mediated cAMP reduction
B) Neurons in the supraoptic nucleus synthesize dopamine and release it directly into the posterior pituitary, where it binds D1 receptors on lactotroph cell projections and suppresses prolactin through a Gs-cAMP-dependent mechanism
C) Dopaminergic neurons of the tuberoinfundibular dopaminergic (TIDA) pathway originate in the arcuate nucleus and project to the median eminence, releasing dopamine into portal blood where it binds D2 receptors (D2R) on anterior pituitary lactotroph cells, activating Gi to inhibit adenylyl cyclase and suppress prolactin gene transcription and secretion
D) GABAergic interneurons in the hypothalamus tonically suppress lactotroph activity through direct synaptic inhibition via GABA-A chloride channels expressed on lactotroph cell membranes in the anterior pituitary
E) Opioid peptides secreted from hypothalamic neurons bind mu-opioid receptors on lactotroph cells via the portal circulation, activating Gi to suppress cAMP and directly inhibit prolactin secretion as the primary physiological brake
ANSWER: C
Rationale:
This question asked you to identify the primary inhibitory hypothalamic control pathway for prolactin and its receptor mechanism. Dopamine released from the tuberoinfundibular dopaminergic (TIDA) pathway — arising from arcuate nucleus neurons projecting to the median eminence — is the primary physiological inhibitor of prolactin secretion. Portal blood delivers dopamine to the anterior pituitary, where it binds dopamine type 2 receptors (D2R) on lactotroph cells. D2R is Gi-coupled; Gi activation inhibits adenylyl cyclase, reduces intracellular cAMP, and suppresses both prolactin gene transcription and prolactin exocytosis. This dopamine-D2R inhibitory tone is clinically critical because any drug that blocks D2R will elevate prolactin as a class effect.
Option A: Option A is incorrect because somatostatin does not tonically suppress prolactin; its primary target cells in the anterior pituitary are somatotrophs (for GH suppression), and somatostatin is not the primary prolactin-inhibiting hormone — dopamine holds that role.
Option B: Option B is incorrect because the supraoptic nucleus synthesizes oxytocin and vasopressin, not dopamine; the relevant dopamine neurons originate in the arcuate nucleus, and D1 receptors are not the receptor subtype involved in pituitary prolactin inhibition — D2R is.
Option D: Option D is incorrect because the anterior pituitary is not innervated by direct synaptic connections from hypothalamic neurons; hypothalamic regulation of anterior pituitary function is humoral, mediated by hormones released into portal blood, not via direct synapses.
Option E: Option E is incorrect because while opioids do affect prolactin indirectly by suppressing TIDA neuron activity through mu-opioid receptors expressed on dopaminergic neurons, this is an indirect modulation of the dopaminergic pathway rather than a direct lactotroph inhibitory mechanism; opioids are not the primary physiological brake on prolactin.
8. A 26-year-old woman with schizophrenia is started on risperidone and returns 3 months later reporting amenorrhea and bilateral milky nipple discharge. A serum prolactin level is markedly elevated. Which of the following best explains the mechanism responsible for her symptoms?
A) Risperidone stimulates TRH secretion from the hypothalamus, leading to TRH-driven prolactin release from lactotroph cells through the same Gq-PLC-IP3 pathway activated during primary hypothyroidism
B) Risperidone blocks dopamine type 2 receptors (D2R) on anterior pituitary lactotroph cells, removing the tonic dopaminergic inhibition of prolactin and allowing unrestrained prolactin secretion — a class effect shared by most antipsychotics
C) Risperidone activates prolactin receptors directly on lactotroph cells through partial agonism at the prolactin receptor, bypassing hypothalamic control entirely and stimulating constitutive prolactin gene expression
D) Risperidone inhibits reuptake of dopamine in the tuberoinfundibular dopaminergic (TIDA) pathway, paradoxically increasing synaptic dopamine concentrations at the median eminence and overwhelming lactotroph D2R inhibition by receptor desensitization
E) Risperidone blocks estrogen receptors on lactotroph cells, preventing estrogen-mediated upregulation of a dopamine-degrading enzyme, which indirectly reduces dopamine availability and elevates prolactin
ANSWER: B
Rationale:
This question asked you to identify the mechanism by which risperidone produces hyperprolactinemia. Risperidone is a second-generation antipsychotic that is a potent D2R antagonist. By blocking D2R on pituitary lactotroph cells, risperidone removes the tonic dopaminergic inhibition that normally suppresses prolactin secretion. The result is unrestrained prolactin release, producing the clinical syndrome of hyperprolactinemia — manifesting as amenorrhea (via suppression of GnRH pulsatility by elevated prolactin), galactorrhea (via mammary gland stimulation), and in men, sexual dysfunction and gynecomastia. D2R blockade-driven hyperprolactinemia is a class effect of most antipsychotics (both first-generation and most second-generation agents).
Option A: Option A is incorrect because risperidone does not stimulate TRH secretion; its hyperprolactinemic effect is due to direct D2R blockade at the pituitary, not through TRH-driven stimulation of lactotrophs — TRH-driven hyperprolactinemia is the mechanism seen in primary hypothyroidism, not antipsychotic use.
Option C: Option C is incorrect because risperidone does not directly bind or activate prolactin receptors; it is an antipsychotic with primary activity at dopamine and serotonin receptors, and prolactin elevation occurs because of D2R blockade removing inhibition, not through receptor agonism at the lactotroph.
Option D: Option D is incorrect because risperidone does not inhibit dopamine reuptake; that mechanism describes drugs such as cocaine and methylphenidate. Antipsychotics work by receptor blockade, not reuptake inhibition, and increased synaptic dopamine in the TIDA pathway would actually oppose prolactin elevation rather than cause it.
Option E: Option E is incorrect because risperidone does not act through estrogen receptor blockade or through modulation of dopamine-degrading enzymes; the hyperprolactinemia is a direct consequence of D2R antagonism at the pituitary lactotroph.
9. A psychiatrist is managing a 30-year-old woman with schizophrenia who has developed symptomatic hyperprolactinemia on risperidone, including amenorrhea and galactorrhea. The team considers switching to an antipsychotic less likely to elevate prolactin. Which of the following antipsychotics is correctly identified as prolactin-sparing and the mechanism by which it avoids hyperprolactinemia?
A) Haloperidol — a first-generation antipsychotic that spares prolactin because it preferentially blocks D1 receptors in the prefrontal cortex rather than D2 receptors at the pituitary lactotroph
B) Olanzapine — a second-generation antipsychotic that spares prolactin because it is a selective muscarinic antagonist and does not interact with dopamine receptors at the pituitary at clinically relevant concentrations
C) Risperidone — already prolactin-sparing among second-generation antipsychotics because its serotonin 5-HT2A antagonism counterbalances D2 blockade and prevents the net increase in prolactin secretion
D) Aripiprazole — a partial D2 receptor agonist that maintains enough dopaminergic tone at the pituitary D2R to suppress prolactin while providing sufficient D2 blockade in mesolimbic pathways to achieve antipsychotic efficacy; it can normalize prolactin when added to a prolactin-elevating antipsychotic regimen
E) Clozapine — prolactin-sparing because it is an irreversible D2 receptor antagonist that produces permanent receptor downregulation at the pituitary, eventually reducing the number of available D2R and paradoxically restoring dopamine sensitivity
ANSWER: D
Rationale:
This question asked you to identify a prolactin-sparing antipsychotic and its mechanism. Aripiprazole is a partial D2 receptor agonist: at the pituitary lactotroph, where dopamine tone is already physiologically present, aripiprazole's partial agonism provides sufficient D2R activation to maintain inhibition of prolactin secretion. In mesolimbic pathways, where pathological dopamine excess drives psychotic symptoms, aripiprazole's partial agonism functions as functional antagonism by reducing dopamine signaling below the level of full agonism. This unique pharmacological profile makes aripiprazole prolactin-sparing and explains its clinical use as an add-on to normalize prolactin in patients on prolactin-elevating antipsychotics who cannot be switched. Clozapine and quetiapine are also prolactin-sparing but through a different mechanism (very low D2 occupancy at clinically effective doses).
Option A: Option A is incorrect because haloperidol is a first-generation antipsychotic that is a potent D2 receptor antagonist — it reliably and substantially elevates prolactin and is one of the most prolactin-elevating antipsychotics available; it does not preferentially block D1 receptors.
Option B: Option B is incorrect because olanzapine is not prolactin-sparing; it is a D2 and 5-HT2A antagonist that does elevate prolactin, though less predictably than risperidone; its anticholinergic (muscarinic) properties are not the basis for any prolactin-sparing effect.
Option C: Option C is incorrect because risperidone is specifically one of the most potently prolactin-elevating second-generation antipsychotics — it is emphatically not prolactin-sparing; the patient's hyperprolactinemia in the stem was caused by risperidone, making this option self-evidently incorrect.
Option E: Option E is incorrect because clozapine's prolactin-sparing property is due to its very low D2 receptor occupancy at therapeutic doses (approximately 40 to 60% versus more than 80% for haloperidol) and its rapid dissociation from D2R ("fast off" kinetics), not because it is an irreversible receptor antagonist — irreversible antagonism would cause persistent D2 blockade and would elevate, not spare, prolactin.
10. A 39-week pregnant patient requires induction of labor. The obstetrician orders synthetic oxytocin (Pitocin) intravenously. The patient asks why the uterus is so responsive to oxytocin only near term but not earlier in pregnancy. Which of the following best explains the pharmacological basis for the marked increase in uterine sensitivity to oxytocin at term gestation?
A) The oxytocin receptor (OTR) undergoes a conformational change near term that converts it from a Gi-coupled to a Gq-coupled receptor, dramatically increasing the potency of calcium-mediated uterine contractions
B) Near term, the fetal adrenal gland secretes large quantities of ACTH into the amniotic fluid, which cross-reacts with OTR in the myometrium and primes the receptor for oxytocin binding by reducing its desensitization threshold
C) The placenta dramatically increases oxytocin synthesis in the third trimester, saturating the OTR in the myometrium with endogenous ligand and upregulating receptor expression through a positive feedback mechanism
D) Progesterone produced by the corpus luteum rises sharply near term and directly upregulates OTR gene expression in myometrial cells, priming the uterus for the oxytocin-induced contractions of labor
E) Estrogen-driven upregulation of oxytocin receptor (OTR) expression in myometrial cells increases markedly near term as estrogen levels rise relative to progesterone, increasing the density of OTR on the cell surface and thereby amplifying uterine sensitivity to oxytocin
ANSWER: E
Rationale:
This question asked you to explain why uterine sensitivity to oxytocin increases near term. The oxytocin receptor (OTR) is a Gq-coupled GPCR expressed on uterine myometrial cells; its activation mobilizes intracellular calcium to drive smooth muscle contraction. The density of OTR on myometrial cells is regulated by the hormonal milieu of pregnancy: rising estrogen levels near term — particularly as the estrogen-to-progesterone ratio increases in the final weeks of gestation — upregulate OTR expression in the myometrium. This increase in receptor density dramatically amplifies uterine responsiveness to circulating oxytocin, even before endogenous oxytocin levels rise significantly. Synthetic oxytocin (Pitocin) exploits this receptor upregulation to induce or augment labor effectively at term.
Option A: Option A is incorrect because the OTR does not change its G protein coupling from Gi to Gq at term; it is Gq-coupled throughout pregnancy — the change in sensitivity is due to receptor density (expression level), not a change in receptor coupling subtype.
Option B: Option B is incorrect because fetal ACTH does not cross-react with the oxytocin receptor; ACTH binds ACTH receptors on the adrenal cortex, and there is no pharmacological basis for ACTH-OTR cross-reactivity or priming.
Option C: Option C is incorrect because the placenta does not produce substantial quantities of oxytocin that act in a positive-feedback autocrine manner to upregulate OTR; OTR upregulation is driven by estrogen, not by endogenous oxytocin ligand concentration.
Option D: Option D is incorrect because progesterone generally maintains uterine quiescence during pregnancy and tends to counteract, not promote, OTR upregulation; it is the withdrawal of progesterone dominance and the rise in estrogen near term that drives OTR upregulation — progesterone rising sharply near term would be physiologically inconsistent with the onset of labor.
11. A 19-year-old male with central diabetes insipidus (CDI) due to a hypothalamic injury is treated with intranasal desmopressin (DDAVP). A colleague asks why desmopressin is preferred over native vasopressin (ADH) for long-term management of CDI. Which of the following best explains the pharmacological advantage of desmopressin over native vasopressin in this clinical setting?
A) Desmopressin has a longer plasma half-life than native vasopressin and crosses the blood-brain barrier more readily, directly stimulating hypothalamic osmoreceptors to restore normal thirst sensation in addition to correcting renal water handling
B) Desmopressin is a synthetic vasopressin analog with selective V2 receptor agonism and negligible V1a receptor activity; V2 receptor activation in the renal collecting duct inserts aquaporin-2 water channels to produce antidiuresis, while the absence of V1a agonism avoids vasoconstriction and the cardiovascular complications associated with native vasopressin
C) Desmopressin is a V1a receptor agonist that selectively targets vascular smooth muscle to normalize blood pressure in CDI, indirectly reducing the demand for antidiuresis by correcting the hypotension-driven polyuria seen in these patients
D) Native vasopressin cannot be administered intranasally because it is too large a molecule to cross nasal mucosa, while desmopressin's smaller molecular size and modified structure allows intranasal absorption — this route difference is the primary clinical reason for preferring desmopressin
E) Desmopressin blocks V2 receptors in the renal medulla while simultaneously activating V1b receptors in the pituitary to stimulate ACTH release, providing combined antidiuretic and adrenocortical support in patients with pan-hypopituitarism
ANSWER: B
Rationale:
This question asked you to identify why desmopressin is preferred over native vasopressin for central diabetes insipidus. Vasopressin (ADH) acts on three receptor subtypes: V1a receptors (Gq-coupled, on vascular smooth muscle — mediate vasoconstriction and increase blood pressure), V1b receptors (Gq-coupled, on anterior pituitary corticotrophs — stimulate ACTH release), and V2 receptors (Gs-coupled, on renal collecting duct principal cells — drive aquaporin-2 insertion and antidiuresis). Native vasopressin activates all three subtypes; chronic administration at antidiuretic doses carries a risk of vasoconstriction and blood pressure elevation. Desmopressin is a synthetic analog modified to have highly selective V2 agonism with negligible V1a activity, producing effective antidiuresis without the vasoconstriction risk — making it safe for long-term outpatient management.
Option A: Option A is incorrect because desmopressin does not cross the blood-brain barrier to stimulate hypothalamic osmoreceptors; its site of action is the renal collecting duct V2 receptor, not the central nervous system; and desmopressin does not restore thirst sensation, which requires intact hypothalamic osmoreceptor function.
Option C: Option C is incorrect because desmopressin is not a V1a receptor agonist; it has negligible V1a activity, which is precisely its pharmacological advantage over native vasopressin — describing desmopressin as a V1a agonist is a direct inversion of its receptor selectivity profile.
Option D: Option D is incorrect because while desmopressin is available in intranasal form, this is not the primary pharmacological reason for preferring it over native vasopressin; native vasopressin can also be administered intranasally, and the key advantage is receptor selectivity (V2 without V1a), not route of administration.
Option E: Option E is incorrect because desmopressin is a V2 receptor agonist, not a V2 blocker; vaptans (tolvaptan, conivaptan) are the V2 antagonists used for hyponatremia; additionally, desmopressin does not have meaningful V1b agonist activity.
12. A patient with acromegaly inadequately controlled on octreotide LAR is switched to pasireotide LAR. Two months later, fasting glucose is 210 mg/dL; the patient was previously normoglycemic. Which of the following best explains the mechanism responsible for pasireotide's substantially higher rate of hyperglycemia compared to octreotide?
A) Pasireotide's pan-SSTR agonism includes potent SSTR5 activation on pancreatic beta cells, which suppresses insulin secretion more profoundly than the partial SSTR5 engagement of octreotide; combined with SSTR2-mediated glucagon suppression, the net effect is impaired insulin secretion relative to glucose load, producing hyperglycemia in the majority of patients
B) Pasireotide has a longer plasma half-life than octreotide due to its larger molecular size, maintaining higher somatostatin receptor occupancy between doses; the prolonged receptor engagement produces tachyphylaxis of hepatic insulin receptors, reducing peripheral glucose uptake
C) Pasireotide crosses the blood-brain barrier more readily than octreotide and activates hypothalamic SSTR3 receptors that suppress the satiety signal, increasing caloric intake and producing obesity-related insulin resistance over months of treatment
D) The PLGA depot formulation of pasireotide LAR releases the drug at a faster rate than octreotide LAR, producing concentration-dependent direct pancreatic beta cell toxicity through oxidative stress rather than through a receptor-mediated mechanism
E) Pasireotide preferentially activates SSTR1 receptors on pancreatic alpha cells, stimulating glucagon secretion and producing hyperglycemia through glucagon-driven hepatic glucose output rather than through any effect on insulin secretion
ANSWER: A
Rationale:
This question asked you to explain why pasireotide causes substantially higher rates of hyperglycemia compared to octreotide. The mechanism is receptor subtype-specific. Pancreatic beta cells express both SSTR2 and SSTR5; SSTR5 is particularly important in mediating insulin secretion inhibition. Pasireotide, as a pan-SSTR agonist with high affinity for SSTR1, SSTR2, SSTR3, and SSTR5, produces potent SSTR5-mediated insulin suppression. Simultaneously, SSTR2-mediated suppression of glucagon from alpha cells occurs with both octreotide and pasireotide, but the insulin suppression with pasireotide is disproportionately greater, resulting in a net state of impaired insulin secretion relative to the ambient glucose load. Clinical trial data show hyperglycemia in approximately 73% of patients on pasireotide compared with 20 to 30% on octreotide or lanreotide, and pasireotide-induced hyperglycemia is best managed with GLP-1 receptor agonists, which bypass the somatostatin-inhibited cAMP/PKA pathway and stimulate insulin secretion through a separate mechanism.
Option B: Option B is incorrect because pasireotide's higher hyperglycemia rate is not due to tachyphylaxis of hepatic insulin receptors from prolonged occupancy; it is a direct receptor-mediated suppression of pancreatic insulin secretion through SSTR5 activation, and this mechanism is well characterized.
Option C: Option C is incorrect because pasireotide does not achieve meaningful CNS penetration to activate hypothalamic SSTR3 and alter feeding behavior; its hyperglycemic effect occurs acutely and is mediated at the pancreatic level, not through obesity-related insulin resistance over months.
Option D: Option D is incorrect because the PLGA depot release rate is not the basis for differential hyperglycemia risk between these two agents; the depot technology is similar, and direct beta cell toxicity is not the established mechanism — receptor-mediated insulin suppression is.
Option E: Option E is incorrect because pasireotide does not preferentially activate SSTR1 on alpha cells to stimulate glucagon; SSTR activation is inhibitory, not stimulatory, across all five receptor subtypes — somatostatin analogs suppress glucagon secretion, not increase it.
13. Native GnRH has a plasma half-life of only 2 to 4 minutes, making it unsuitable as a therapeutic agent in its unmodified form. Leuprolide, a GnRH agonist used clinically, has a plasma half-life of 3 to 8 hours when given as a subcutaneous injection. Which of the following structural modifications is primarily responsible for this dramatic half-life extension?
A) Leuprolide is conjugated to polyethylene glycol (PEG) at its N-terminus, increasing its hydrodynamic radius and preventing glomerular filtration — thereby reducing renal clearance and extending the plasma half-life
B) Leuprolide is formulated as a pro-drug that requires hepatic activation by cytochrome P450 3A4 (CYP3A4); the rate-limiting hepatic biotransformation step slows the appearance of active drug in plasma, producing a pharmacokinetic profile that mimics extended half-life
C) Substitution of a D-amino acid (D-leucine) at position 6 of the GnRH decapeptide prevents enzymatic recognition and cleavage at a peptidase-susceptible site, protecting the molecule from rapid plasma degradation and extending the half-life from minutes to hours
D) Leuprolide contains a non-hydrolyzable phosphonate bond at the central peptide linkage that the serum peptidases cannot cleave, preserving the native amino acid sequence while rendering the molecule resistant to endopeptidase degradation
E) Leuprolide is encapsulated in PLGA microspheres that prevent its contact with plasma peptidases entirely; the extended half-life reflects microsphere dissolution kinetics rather than any intrinsic molecular modification of the peptide itself
ANSWER: C
Rationale:
This question asked you to identify the structural basis for leuprolide's extended half-life compared to native GnRH. Native GnRH is a decapeptide rapidly degraded by serum and tissue peptidases, with a plasma half-life of 2 to 4 minutes. The primary strategy for extending GnRH analog half-life is substitution of D-amino acids at peptidase-susceptible cleavage sites, particularly at position 6 of the GnRH decapeptide. Peptidases recognize and cleave the L-amino acid configuration; substituting a D-amino acid (such as D-leucine in leuprolide, or D-tryptophan in other analogs) at position 6 creates a steric mismatch that prevents enzymatic recognition, blocking cleavage at that site and extending the plasma half-life from minutes to several hours. C-terminal amidation (replacing the free carboxyl group with an amide, as in leuprolide) further retards carboxy-peptidase attack.
Option A: Option A is incorrect because PEGylation is a strategy used with larger peptide hormones and some monoclonal antibodies to reduce renal clearance; it is not the mechanism employed in GnRH analog design — D-amino acid substitution is the relevant strategy for this drug class.
Option B: Option B is incorrect because leuprolide is not a pro-drug requiring hepatic CYP3A4 activation; it is an active peptide that exerts its effect directly at GnRH receptors without metabolic conversion, and CYP3A4 metabolism is relevant to the oral non-peptide GnRH antagonists such as elagolix, not to leuprolide.
Option D: Option D is incorrect because leuprolide does not contain non-hydrolyzable phosphonate bonds; the resistance to degradation is achieved through D-amino acid substitution changing the stereochemical configuration recognized by peptidases, not through backbone modification to a non-peptide linkage.
Option E: Option E is incorrect because leuprolide itself is structurally modified to resist degradation — the extended plasma half-life (3 to 8 hours for subcutaneous leuprolide acetate solution, not depot) reflects the intrinsic molecular stability conferred by D-amino acid substitution; the PLGA microsphere depot formulation converts this to weeks-long drug release, but that is a separate formulation technology layered on top of the already-modified peptide.
14. Octreotide has a plasma half-life of approximately 1.7 to 2 hours after subcutaneous injection, which would require multiple daily injections for chronic acromegaly management. Octreotide LAR (long-acting release) achieves equivalent GH suppression with once-monthly intramuscular dosing. Which of the following best describes the technology responsible for converting a 2-hour half-life peptide into a monthly formulation?
A) Octreotide LAR uses a pH-sensitive hydrogel polymer matrix that is stable at physiological pH but dissolves rapidly in the acidic microenvironment of muscle tissue, producing a controlled release profile limited to the time required for local acidification and re-neutralization
B) Octreotide LAR contains a prodrug form of octreotide that is slowly activated by intramuscular esterases over 28 days; each day's dose of activated octreotide is released from the inactive depot in a pulse corresponding to local esterase activity
C) Octreotide LAR microencapsulates the drug in a protein-based shell derived from albumin; the shell is slowly digested by tissue proteases over 28 days, releasing active octreotide at a controlled rate determined by local protease concentration
D) Octreotide LAR encapsulates octreotide in poly(lactic-co-glycolic acid) (PLGA) biodegradable polymer microspheres that hydrolyze slowly after intramuscular injection, releasing drug at a controlled rate over 28 days as the polymer matrix degrades — converting a short-acting peptide into a once-monthly administration
E) Octreotide LAR uses a cholesterol-ester conjugate in which octreotide is covalently bound to a lipid carrier; the conjugate partitions into the muscle lipid compartment after injection and slowly diffuses out of the hydrophobic depot as free peptide over approximately 28 days
ANSWER: D
Rationale:
This question asked you to identify the specific formulation technology used in long-acting somatostatin analogs such as octreotide LAR. Poly(lactic-co-glycolic acid) (PLGA) microsphere technology is the foundational depot formulation system used in octreotide LAR and leuprolide acetate for depot suspension. PLGA is a biodegradable copolymer approved for injectable pharmaceutical use; after intramuscular or subcutaneous injection, the microspheres hydrolize slowly as the ester bonds in the polymer backbone are cleaved by water and tissue esterases, releasing encapsulated drug at a rate governed by microsphere size, polymer ratio, and drug loading. For octreotide LAR, this produces near-zero-order drug release over approximately 28 days, maintaining therapeutic plasma concentrations with a single monthly injection.
Option A: Option A is incorrect because PLGA degradation is not pH-sensitive in the clinically relevant sense described; PLGA hydrolysis proceeds at physiological pH via ester bond cleavage over days to weeks — it is not triggered by local acidification.
Option B: Option B is incorrect because octreotide LAR does not contain a prodrug; octreotide itself is encapsulated in its active form within the polymer microspheres and is released as active drug upon microsphere hydrolysis.
Option C: Option C is incorrect because octreotide LAR does not use an albumin-based protein shell; PLGA is a synthetic polymer, not a protein-based material — the degradation is by ester hydrolysis, not protease digestion.
Option E: Option E is incorrect because octreotide is not conjugated to a cholesterol-ester lipid carrier in the LAR formulation; lipid-based depot strategies are used for some steroids and small molecule drugs, but PLGA microsphere encapsulation is the technology used for octreotide LAR; lanreotide Autogel uses a different approach (deep subcutaneous self-forming semisolid depot), but neither uses lipid conjugation.
15. A 33-year-old woman with endometriosis-associated pelvic pain is started on elagolix. Her primary care physician is reviewing her medication list and notes she is also taking a moderate CYP3A4 inducer. Which of the following statements about elagolix most accurately explains why this drug interaction is clinically important?
A) Elagolix is a peptide-based GnRH antagonist whose primary elimination route is renal excretion of intact peptide; CYP3A4 inducers reduce renal CYP3A4 activity and paradoxically increase elagolix plasma concentrations by impairing urinary metabolite formation
B) Elagolix is converted by CYP3A4 to an active metabolite that is the primary mediator of GnRH receptor antagonism; CYP3A4 inducers increase active metabolite formation and risk producing excessive HPG axis suppression and hypo-estrogenism
C) Elagolix is a peptide GnRH agonist similar in structure to leuprolide; CYP3A4 inducers reduce plasma concentrations of elagolix through accelerated hepatic degradation, producing a paradoxical flare in estrogen levels that exacerbates endometriosis symptoms
D) Elagolix is a P-glycoprotein (P-gp) substrate; CYP3A4 inducers also co-induce P-gp in intestinal enterocytes, increasing efflux of elagolix back into the gut lumen and reducing oral bioavailability, which is the primary mechanism of the drug interaction
E) Elagolix is a non-peptide small molecule GnRH receptor antagonist with oral bioavailability of approximately 57% that is metabolized predominantly by CYP3A4; co-administration with a CYP3A4 inducer accelerates its hepatic metabolism, reducing plasma elagolix concentrations and potentially diminishing its suppression of estrogen-dependent endometriosis pain
ANSWER: E
Rationale:
This question asked you to apply knowledge of elagolix's pharmacokinetic profile to a drug interaction scenario. Elagolix is a non-peptide small molecule — structurally distinct from peptide-based GnRH analogs such as leuprolide — that was designed to achieve oral bioavailability by eliminating the peptide backbone subject to gastrointestinal degradation and poor membrane permeability. It has oral bioavailability of approximately 57% and is metabolized predominantly via CYP3A4 with a secondary contribution from CYP2C8. The short plasma half-life of 4 to 6 hours allows dose-dependent partial or full HPG axis suppression based on the 150 mg once-daily versus 200 mg twice-daily regimens. A CYP3A4 inducer increases hepatic CYP3A4 expression and activity, accelerating elagolix metabolism and reducing its plasma concentrations, potentially rendering the regimen therapeutically inadequate for pain suppression.
Option A: Option A is incorrect because elagolix is not a peptide and is not primarily eliminated by renal excretion of intact drug; it is a small molecule metabolized hepatically by CYP3A4, making hepatic drug interactions the key concern, not renal CYP3A4 (which is pharmacologically negligible for this drug).
Option B: Option B is incorrect because elagolix is itself the active drug at the GnRH receptor, not a prodrug that requires CYP3A4 activation to generate an active metabolite; the CYP3A4 pathway converts it to inactive metabolites, so inducers decrease active drug levels rather than increase active metabolite formation.
Option C: Option C is incorrect because elagolix is a GnRH receptor antagonist, not an agonist — it produces immediate suppression of LH and FSH without an initial hormonal flare, which is one of its pharmacological advantages over GnRH agonists; describing it as a GnRH agonist similar to leuprolide is a fundamental pharmacological error.
Option D: Option D is incorrect because while elagolix's P-gp interactions are limited, the primary CYP3A4 interaction operates through hepatic metabolism of the absorbed drug, not through intestinal P-gp efflux; P-gp co-induction is a more significant mechanism for drugs like relugolix, which is a P-gp and BCRP substrate.
16. A 42-year-old woman undergoes workup for hypercortisolism. Her 24-hour urine free cortisol is elevated, and low-dose dexamethasone suppression testing fails. A high-dose dexamethasone suppression test shows partial cortisol suppression. She then undergoes a CRH stimulation test: after intravenous CRH administration, her plasma ACTH rises by more than 50% from baseline and her cortisol rises accordingly. Which of the following interpretations of this CRH stimulation test result is most consistent with the available data?
A) The exaggerated ACTH response confirms ectopic ACTH syndrome, because ectopic ACTH-secreting tumors are uniquely responsive to exogenous CRH while pituitary adenomas have already downregulated their CRH receptors due to chronic autocrine stimulation
B) The exaggerated ACTH response is most consistent with pituitary-dependent Cushing disease, in which the ACTH-secreting pituitary adenoma retains partial CRH responsiveness (CRH-R1 expression), producing an exaggerated ACTH rise after exogenous CRH; adrenal-dependent Cushing syndrome would show no ACTH rise because autonomous adrenal cortisol suppresses pituitary CRH-R1 signaling
C) The exaggerated ACTH response rules out a pituitary adenoma, because pituitary adenomas produce autonomous ACTH that is constitutively elevated and cannot be further stimulated by exogenous CRH due to receptor saturation at baseline levels
D) The test result is non-diagnostic because CRH stimulation testing cannot distinguish between pituitary and ectopic ACTH sources — all ACTH-secreting tumors, regardless of location, express CRH-R1 and respond to exogenous CRH with proportional ACTH rises
E) The absence of ACTH suppression despite exogenous CRH confirms primary adrenal Cushing syndrome, because normal adrenal tissue suppresses ACTH through negative feedback and autonomous adrenal hypercortisolism is uniquely identified by failure to suppress after CRH
ANSWER: B
Rationale:
This question asked you to interpret a CRH stimulation test result in the context of Cushing syndrome workup. In pituitary-dependent Cushing disease (caused by an ACTH-secreting pituitary adenoma), the adenoma cells retain partial CRH responsiveness through preserved CRH-R1 expression. Exogenous CRH (ovine or human CRH, 1 mcg/kg IV) produces an exaggerated ACTH rise — typically defined as greater than 35 to 50% increase from baseline — along with a corresponding cortisol rise. In contrast, adrenal-dependent Cushing syndrome (autonomous cortisol production from an adrenal adenoma or carcinoma) suppresses pituitary ACTH at baseline, and exogenous CRH produces no ACTH rise because the pituitary corticotrophs are chronically suppressed by negative feedback. This differential response is the diagnostic utility of the CRH stimulation test, particularly when combined with inferior petrosal sinus sampling to lateralize a pituitary adenoma.
Option A: Option A is incorrect because the interpretation is inverted — ectopic ACTH-secreting tumors are characteristically CRH-unresponsive (they lack functional CRH-R1), and it is the pituitary adenoma that retains partial CRH responsiveness; the stem describes an exaggerated ACTH response, which points toward pituitary origin, not ectopic.
Option C: Option C is incorrect because pituitary adenomas are not excluded by CRH responsiveness — retained CRH-R1 responsiveness in pituitary corticotroph adenomas is precisely why they respond to exogenous CRH; receptor saturation at baseline does not prevent further stimulation in these adenomas.
Option D: Option D is incorrect because CRH stimulation testing does help distinguish pituitary from ectopic ACTH sources — ectopic tumors typically do not respond to CRH, while pituitary adenomas typically do; the test has diagnostic value when interpreted in the clinical context, though it is not perfectly sensitive or specific.
Option E: Option E is incorrect because the test result described is an ACTH rise (exaggerated response), not ACTH suppression; primary adrenal Cushing syndrome would manifest as a flat or absent ACTH response to CRH (because autonomous cortisol already suppresses pituitary ACTH), not as an exaggerated ACTH rise.
17. Native somatostatin has a plasma half-life of 1 to 3 minutes after intravenous infusion, while octreotide has a plasma half-life of approximately 1.7 to 2 hours. Which of the following correctly explains why native somatostatin's pharmacokinetic profile makes it unsuitable as a chronic therapeutic agent, and what structural approach was used to overcome this limitation in designing octreotide?
A) Native somatostatin is rapidly degraded by serum and tissue peptidases within 1 to 3 minutes, making sustained therapeutic concentrations impossible without continuous IV infusion; octreotide was engineered as a stable cyclic octapeptide with D-amino acid substitutions at key positions, retarding peptidase cleavage and extending the half-life to hours suitable for subcutaneous dosing
B) Native somatostatin is cleared primarily by glomerular filtration due to its small molecular size; octreotide was conjugated to a large protein carrier to increase its molecular weight above the renal filtration threshold, shifting clearance from renal to hepatic and extending the plasma half-life
C) Native somatostatin binds all five SSTR subtypes equally and undergoes rapid receptor-mediated endocytosis followed by lysosomal degradation at each receptor; octreotide was designed to selectively avoid SSTR3, the receptor subtype associated with the fastest internalization, prolonging octreotide surface receptor occupancy and apparent plasma half-life
D) Native somatostatin has very high lipid solubility and rapidly partitions into adipose tissue depots, producing a large apparent volume of distribution that dilutes plasma concentrations to subtherapeutic levels; octreotide was made more hydrophilic to reduce adipose partitioning and maintain therapeutic plasma levels
E) Native somatostatin is inactivated within seconds by a specific somatostatin-degrading enzyme (somatostatinase) expressed only on hypothalamic portal endothelial cells; octreotide was designed with a bulky C-terminal group that sterically blocks somatostatinase binding while preserving SSTR affinity
ANSWER: A
Rationale:
This question asked you to connect somatostatin's pharmacokinetic liability to the structural design of octreotide. Native somatostatin-14 and somatostatin-28 are rapidly degraded in plasma by non-specific peptidases (endopeptidases and exopeptidases), yielding a plasma half-life of 1 to 3 minutes. This makes continuous intravenous infusion the only feasible method for maintaining therapeutic concentrations with native somatostatin — clinically impractical for chronic conditions such as acromegaly or carcinoid syndrome. Octreotide was engineered by taking the structurally essential cyclic core of somatostatin-14 and building a four-amino-acid cyclic octapeptide with D-phenylalanine (D-Phe) and D-tryptophan (D-Trp) substitutions at peptidase-susceptible positions; these D-amino acid substitutions prevent peptidase recognition and cleavage, extending the half-life to approximately 1.7 to 2 hours for subcutaneous injection — sufficient for two-to-three-times-daily dosing, or once monthly with the PLGA depot formulation.
Option B: Option B is incorrect because native somatostatin is not primarily cleared by glomerular filtration based on small molecular size; peptide degradation by circulating and tissue peptidases is the dominant clearance mechanism, and octreotide is not conjugated to a protein carrier in its standard form — PEGylation or albumin fusion is not part of the octreotide design.
Option C: Option C is incorrect because receptor-mediated endocytosis of SSTR3 is not the primary mechanism of somatostatin clearance; plasma peptidase degradation is the critical limitation, and octreotide's SSTR subtype selectivity (SSTR2/SSTR5) was chosen for pharmacodynamic efficacy, not to avoid rapid internalization via SSTR3.
Option D: Option D is incorrect because native somatostatin is a hydrophilic peptide, not a lipophilic molecule that would partition extensively into adipose tissue; the clearance problem is enzymatic degradation, not redistribution into lipid compartments.
Option E: Option E is incorrect because there is no single enzyme called somatostatinase expressed specifically on portal endothelial cells; somatostatin degradation is mediated by non-specific peptidases broadly distributed throughout the plasma and tissues, not a specific endothelial enzyme.
18. A patient with euvolemic hyponatremia is found to have syndrome of inappropriate antidiuretic hormone secretion (SIADH). The team considers initiating tolvaptan. Before prescribing, a student asks how the normal antidiuretic hormone (ADH) signaling pathway works in the renal collecting duct. Which of the following correctly describes the V2 receptor signaling mechanism by which ADH produces antidiuresis?
A) ADH binds V2 receptors on renal collecting duct principal cells, activating Gq to stimulate phospholipase C, which generates IP3 and releases calcium from the endoplasmic reticulum to trigger aquaporin-2 (AQP2) exocytosis directly from calcium-sensitive secretory vesicles
B) ADH binds V2 receptors on renal collecting duct principal cells, activating Gi to reduce intracellular cAMP; the decrease in cAMP activates a phosphodiesterase cascade that dephosphorylates aquaporin-2 vesicle fusion proteins, inserting AQP2 water channels into the apical membrane
C) ADH binds V2 receptors on renal collecting duct principal cells, activating Gs to stimulate adenylyl cyclase, raising intracellular cAMP and activating protein kinase A (PKA); PKA phosphorylates aquaporin-2 (AQP2) vesicles, driving their fusion with the apical membrane and inserting water channels to allow water reabsorption and concentrate the urine
D) ADH binds V1a receptors (not V2) on renal collecting duct principal cells, activating Gq to mobilize intracellular calcium; calcium-calmodulin complexes phosphorylate aquaporin-2, triggering its insertion into the basolateral membrane to allow transcellular water movement from lumen to interstitium
E) ADH binds V2 receptors on renal collecting duct intercalated cells, activating Gs to stimulate adenylyl cyclase; the resulting cAMP activates protein kinase A which phosphorylates H+-ATPase pumps on the apical membrane, coupling urinary acidification to aquaporin-2 insertion in a coordinated antidiuretic response
ANSWER: C
Rationale:
This question asked you to trace the V2 receptor signaling cascade responsible for ADH-mediated antidiuresis. ADH (vasopressin) binds V2 receptors expressed on the principal cells of the renal collecting duct. V2 receptors are Gs-coupled GPCRs: Gs activates adenylyl cyclase, which converts ATP to cAMP, raising intracellular cAMP concentration. Elevated cAMP activates protein kinase A (PKA), which phosphorylates aquaporin-2 (AQP2) water channels stored in intracellular vesicles. Phosphorylated AQP2 vesicles fuse with the apical (luminal) membrane of principal cells, inserting functional water channels that allow water to move osmotically from the tubular lumen into the hypertonic medullary interstitium — concentrating the urine and retaining water. Tolvaptan is a selective V2 receptor antagonist that blocks this Gs-cAMP-PKA-AQP2 pathway, preventing water reabsorption and producing a free water diuresis (aquaresis) that corrects hyponatremia in SIADH.
Option A: Option A is incorrect because V2 receptors are Gs-coupled, not Gq-coupled; the Gq-IP3-calcium pathway applies to V1a and V1b receptors, not V2 receptors; AQP2 insertion is driven by PKA-mediated phosphorylation downstream of cAMP, not by direct calcium-triggered vesicle exocytosis.
Option B: Option B is incorrect because V2 receptors activate Gs (stimulatory), not Gi (inhibitory); Gi coupling that reduces cAMP is characteristic of V1b and somatostatin receptors, not V2 receptors — the description given would produce effects opposite to antidiuresis.
Option D: Option D is incorrect because ADH's renal antidiuretic action is mediated through V2 receptors, not V1a receptors; V1a receptors are Gq-coupled and mediate vascular smooth muscle contraction (vasoconstriction), not renal water reabsorption; additionally, AQP2 is inserted into the apical (luminal) membrane, not the basolateral membrane.
Option E: Option E is incorrect because AQP2 insertion occurs in principal cells, not intercalated cells; intercalated cells mediate urinary acid-base handling (H+ secretion and HCO3- reabsorption) and do not express AQP2; the coupling of urinary acidification to antidiuresis described in this option does not reflect established V2 receptor pharmacology.
19. A 68-year-old man with metastatic castration-sensitive prostate cancer is started on relugolix, an oral GnRH antagonist. His cardiologist also prescribes a P-glycoprotein (P-gp) inhibitor for a concurrent condition. The oncologist flags this combination as potentially dangerous. Which of the following best explains the pharmacokinetic basis for this drug interaction and its clinical consequence?
A) P-gp inhibitors block the renal tubular secretion of relugolix, reducing its urinary clearance and doubling its plasma half-life; the resulting accumulation produces sustained hypotestosteronemia that cannot be reversed by drug discontinuation for several weeks
B) Relugolix is a potent inducer of P-gp expression in the small intestine; adding a P-gp inhibitor counteracts this induction, restoring baseline intestinal P-gp activity and paradoxically reducing relugolix oral bioavailability to sub-therapeutic levels
C) P-gp inhibitors reduce the biliary excretion of relugolix by blocking the hepatocanalicular P-gp transporter responsible for relugolix elimination into bile, decreasing first-pass extraction and increasing systemic relugolix exposure to potentially toxic concentrations
D) Relugolix is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in the intestinal epithelium; P-gp inhibitors reduce efflux transport of relugolix back into the gut lumen during absorption, markedly increasing oral bioavailability and plasma exposure — a potentially dangerous increase in exposure that can deepen HPG axis suppression and worsen cardiovascular risk
E) Relugolix inhibits P-gp in the blood-brain barrier; co-administration with a P-gp inhibitor produces additive CNS P-gp blockade and increases CNS penetration of relugolix to pharmacologically relevant concentrations, producing neuroendocrine effects including direct hypothalamic GnRH suppression
ANSWER: D
Rationale:
This question asked you to apply knowledge of relugolix's transporter pharmacology to a drug interaction scenario. Relugolix has oral bioavailability of approximately 12%, which is low partly because it is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) — efflux transporters expressed on intestinal epithelial cells that pump drug back into the gut lumen during absorption, limiting bioavailability. When a P-gp inhibitor is co-administered, the efflux of relugolix from enterocytes back into the intestinal lumen is reduced, allowing more drug to pass through the epithelium and enter the portal circulation — markedly increasing plasma relugolix exposure. This can intensify HPG axis suppression and has been associated with increased cardiovascular risk in the context of deeper testosterone suppression; the drug label for relugolix carries specific warnings about P-gp inhibitor interactions. This transporter interaction contrasts with elagolix, whose primary drug interaction risk is via CYP3A4-mediated hepatic metabolism.
Option A: Option A is incorrect because P-gp is not a renal tubular secretion transporter for relugolix; the relevant P-gp interaction occurs at the intestinal epithelium during absorption, not at the renal tubule; and relugolix's HPG axis suppression is rapidly reversible within weeks of discontinuation (a key advantage over GnRH agonists), not prolonged for months.
Option B: Option B is incorrect because relugolix is a substrate of P-gp, not an inducer of P-gp expression; drugs that induce P-gp are typically nuclear receptor ligands (such as rifampin via PXR), not GnRH antagonists — and the direction of the interaction is inverted in this option.
Option C: Option C is incorrect because the clinically relevant P-gp interaction for relugolix is at the intestinal absorptive epithelium, not the hepatocanalicular transporter; relugolix's biliary elimination is not the primary site where P-gp inhibition produces clinically significant changes in exposure.
Option E: Option E is incorrect because relugolix does not meaningfully inhibit P-gp in the blood-brain barrier, and its mechanism of action is peripheral (GnRH receptor antagonism at the pituitary), not central hypothalamic suppression; it does not penetrate the CNS to produce direct hypothalamic effects.
20. A patient with carcinoid syndrome is started on octreotide for flushing and diarrhea. His fasting glucose, previously normal, rises to 148 mg/dL after 3 months of therapy. Which of the following best explains the mechanism by which somatostatin analogs can produce hyperglycemia?
A) Somatostatin analogs activate SSTR2 on pancreatic alpha cells to stimulate glucagon secretion; the resulting hyperglucagonemia drives hepatic glycogenolysis and gluconeogenesis, raising blood glucose through an alpha-cell-mediated mechanism
B) Octreotide inhibits GLP-1 receptor signaling in intestinal L-cells by reducing cAMP through SSTR2-mediated Gi activation, preventing GLP-1 release after meals and eliminating the incretin effect on insulin secretion
C) Octreotide activates SSTR3 in skeletal muscle cells, impairing GLUT4 translocation to the plasma membrane and reducing insulin-stimulated peripheral glucose uptake — the same mechanism as metformin resistance in type 2 diabetes
D) Somatostatin analogs reduce splanchnic blood flow through SSTR2 activation on mesenteric vessels, decreasing intestinal glucose absorption after meals; the resulting delayed glucose absorption paradoxically causes reactive hyperosmolarity in the fasting state, which is misinterpreted as hyperglycemia on routine fasting glucose testing
E) Somatostatin analogs activate SSTR5 on pancreatic beta cells, inhibiting adenylyl cyclase through Gi coupling, reducing intracellular cAMP, and suppressing glucose-stimulated insulin secretion; SSTR2 activation on alpha cells simultaneously suppresses glucagon, but the net effect is impaired insulin secretion relative to glucose load, producing hyperglycemia
ANSWER: E
Rationale:
This question asked you to identify the mechanism of somatostatin analog-induced hyperglycemia. Pancreatic beta cells express SSTR5 (and to a lesser extent SSTR2); activation of these Gi-coupled receptors inhibits adenylyl cyclase, reduces intracellular cAMP, and suppresses glucose-stimulated insulin secretion. Simultaneously, SSTR2 on pancreatic alpha cells inhibits glucagon secretion. However, the insulin suppression is more pharmacodynamically significant than the glucagon suppression at therapeutic analog doses, resulting in net impairment of insulin secretion relative to the glucose load — producing hyperglycemia. This mechanism explains why pasireotide, with its potent pan-SSTR agonism including high SSTR5 affinity, causes hyperglycemia in approximately 73% of patients, while octreotide and lanreotide (SSTR2/SSTR5-selective, with lower relative SSTR5 potency) produce hyperglycemia in approximately 20 to 30% of patients. Treatment of somatostatin analog-induced hyperglycemia often requires GLP-1 receptor agonists, which stimulate insulin secretion through a cAMP-dependent pathway that bypasses the SSTR-mediated Gi suppression.
Option A: Option A is incorrect because somatostatin analog activation of SSTR2 on alpha cells suppresses glucagon secretion — the effect is inhibitory at all SSTR-expressing cells, including alpha cells; somatostatin analogs do not stimulate glucagon release, and the hyperglycemia is not due to hyperglucagonemia.
Option B: Option B is incorrect because while GLP-1 secretion from intestinal L-cells may be modestly affected by somatostatin analogs, this is not the primary mechanism of hyperglycemia; the dominant mechanism is direct SSTR5-mediated suppression of pancreatic beta cell insulin secretion.
Option C: Option C is incorrect because somatostatin analogs do not inhibit GLUT4 translocation in skeletal muscle through SSTR3 activation; peripheral insulin resistance of the GLUT4 variety is the mechanism of type 2 diabetes and metformin resistance, not somatostatin analog-induced hyperglycemia.
Option D: Option D is incorrect because while somatostatin analogs do reduce splanchnic blood flow and intestinal motility, this does not produce fasting hyperglycemia — glucose absorption effects would primarily alter postprandial glucose, not fasting glucose; the fasting glucose elevation described in the stem is due to impaired baseline insulin secretion.
21. A 55-year-old man with locally advanced prostate cancer is started on monthly leuprolide injections. His testosterone level, which initially surged during the first week of treatment (the "flare"), falls to castrate levels by week 4 and remains suppressed throughout therapy. Which of the following best explains the cellular mechanism responsible for the sustained suppression of LH and FSH that follows the initial flare?
A) The initial testosterone flare activates an estrogen receptor-mediated negative feedback loop in the hypothalamus that permanently reduces endogenous GnRH pulse frequency, sustaining pituitary gonadotroph suppression independently of continued leuprolide receptor occupancy
B) Continuous occupancy of the GnRH receptor by leuprolide triggers receptor downregulation through internalization and uncoupling from Gq signaling in pituitary gonadotroph cells; the receptor-depleted gonadotrophs are no longer responsive to either leuprolide or endogenous GnRH, producing sustained LH and FSH suppression as long as continuous agonist exposure is maintained
C) Leuprolide's D-amino acid substitutions cause it to act as a biased agonist that recruits beta-arrestin without activating Gq; beta-arrestin signaling in gonadotrophs activates a phosphodiesterase that degrades all intracellular cAMP, permanently silencing LH and FSH gene transcription through epigenetic histone deacetylation
D) The testosterone surge during the initial flare triggers a direct negative feedback signal at the level of the anterior pituitary, causing gonadotroph cells to undergo apoptosis through a testosterone-induced Fas-FasL pathway; the reduction in gonadotroph cell number is the primary mechanism sustaining castrate testosterone levels on continuous leuprolide therapy
E) Leuprolide is converted by pituitary 5-alpha reductase to a more potent dihydroleuprolide metabolite that has higher GnRH receptor affinity; over weeks, dihydroleuprolide accumulates intracellularly in gonadotrophs and irreversibly alkylates GnRH receptor cysteine residues, producing permanent receptor inactivation
ANSWER: B
Rationale:
This question asked you to explain the receptor-level mechanism by which continuous GnRH agonist therapy produces sustained gonadotropin suppression after the initial hormonal flare. When leuprolide (a long-acting GnRH agonist) produces continuous GnRH receptor occupancy — in contrast to the pulsatile occupancy of endogenous GnRH — the GnRH receptor is not allowed to recover between activations. Sustained Gq activation triggers receptor desensitization: the receptor is phosphorylated by G protein-coupled receptor kinases (GRKs), beta-arrestin is recruited, the receptor uncouples from Gq, and receptor-ligand complexes are internalized via endocytosis. Over days to weeks, receptor density on the gonadotroph cell surface falls markedly (downregulation). The net result is that gonadotroph cells become unable to generate LH and FSH secretory pulses in response to further GnRH or GnRH agonist stimulation, producing the sustained hypogonadotropic state exploited therapeutically for medical castration.
Option A: Option A is incorrect because while testosterone negative feedback does occur at the hypothalamus, the sustained gonadotropin suppression on continuous leuprolide is primarily due to pituitary GnRH receptor downregulation, not a permanent estrogen-receptor-mediated reduction in hypothalamic GnRH pulse generation — patients' LH and FSH rapidly recover after leuprolide is discontinued, confirming that the mechanism is reversible receptor desensitization rather than permanent hypothalamic silencing.
Option C: Option C is incorrect because leuprolide does not act as a biased agonist selecting only beta-arrestin signaling in gonadotrophs; it is a full GnRH receptor agonist that initially activates Gq (producing the testosterone flare), and the subsequent desensitization is the normal consequence of sustained agonist occupancy, not a pharmacologically designed biased signaling pathway.
Option D: Option D is incorrect because gonadotroph apoptosis driven by testosterone-Fas-FasL signaling is not the established mechanism of medical castration with GnRH agonists; gonadotroph cell number is not substantially reduced, and castrate testosterone levels recover upon drug discontinuation, indicating that the mechanism is receptor-level suppression, not permanent cell loss.
Option E: Option E is incorrect because leuprolide is not metabolized by pituitary 5-alpha reductase to a dihydro metabolite, and it does not irreversibly alkylate GnRH receptor cysteine residues; the GnRH receptor downregulation it produces is fully reversible, distinguishing it from alkylating agents that form covalent receptor bonds.
22. A 45-year-old woman underwent transsphenoidal surgery for a large non-functioning pituitary macroadenoma 6 months ago. She now has low free T4 with a TSH that is inappropriately normal rather than elevated. Her physician suspects central hypothyroidism and considers protirelin (synthetic TRH) stimulation testing to evaluate the level of the defect. Which of the following best describes how the TRH stimulation test distinguishes hypothalamic from pituitary causes of central hypothyroidism?
A) In pituitary insufficiency, exogenous TRH administered intravenously produces a blunted or absent TSH response because the thyrotroph cells are damaged or depleted and cannot respond to TRH stimulation; in hypothalamic disease with an intact pituitary, the TSH response to TRH is typically present but may be delayed, reflecting a pituitary that retains the capacity to respond to TRH but has been chronically understimulated by absent endogenous TRH
B) In pituitary insufficiency, exogenous TRH produces an exaggerated TSH response because the thyrotroph cells are hypersensitive due to prolonged absence of endogenous TRH stimulation; in hypothalamic disease, the TSH response to TRH is normal because endogenous TRH continues to maintain pituitary thyrotroph sensitivity
C) The TRH stimulation test cannot distinguish hypothalamic from pituitary causes of central hypothyroidism because TSH secretion is entirely autonomous once thyrotroph cells differentiate; only a direct injection of TSH can reveal pituitary responsiveness to regulatory signals in patients after pituitary surgery
D) In both hypothalamic and pituitary causes of central hypothyroidism, TRH stimulation always produces an identical absent TSH response, because the common final pathway of reduced thyroid hormone negative feedback renders thyrotroph cells uniformly refractory to exogenous TRH in all forms of central hypothyroidism
E) The TRH stimulation test detects pituitary insufficiency by measuring the prolactin response rather than the TSH response; a blunted prolactin rise after TRH indicates pituitary lactotroph damage, which co-localizes with thyrotroph damage and serves as a surrogate marker for central hypothyroidism after pituitary surgery
ANSWER: A
Rationale:
This question asked you to apply knowledge of TRH physiology to the interpretation of protirelin stimulation testing in central hypothyroidism. TRH receptor (TRHR) is expressed on both thyrotroph and lactotroph cells of the anterior pituitary; exogenous TRH can therefore probe pituitary thyrotroph responsiveness directly. In pituitary insufficiency (such as post-surgical thyrotroph damage), the thyrotroph cell mass is reduced or the cells are dysfunctional; intravenous TRH produces a blunted or absent TSH rise because the cells cannot respond normally to TRH receptor stimulation. In hypothalamic disease (isolated TRH deficiency with an intact pituitary), the pituitary thyrotrophs retain functional TRHR and can respond to exogenous TRH — the TSH response is preserved and may even be delayed (with a late-peaking response at 60 minutes rather than the normal 20 to 30 minutes), reflecting a pituitary that was chronically understimulated rather than intrinsically damaged. This distinction was the clinical basis for the TRH stimulation test, which has largely been replaced by modern sensitive TSH assays but retains conceptual importance for understanding HPT axis regulation.
Option B: Option B is incorrect because the response pattern described is inverted — it is hypothalamic disease (not pituitary insufficiency) that shows a preserved or delayed TSH response; pituitary insufficiency produces a blunted or absent response, not an exaggerated one, because damaged thyrotrophs cannot mount a hypersensitive reply.
Option C: Option C is incorrect because TSH secretion is not autonomous once thyrotrophs differentiate; thyrotrophs remain regulated by TRH stimulation and thyroid hormone negative feedback throughout adult life, and the TRH stimulation test specifically probes thyrotroph responsiveness to TRH — this is the test's established mechanistic basis.
Option D: Option D is incorrect because central hypothyroidism of hypothalamic origin and pituitary origin do not produce identical absent TSH responses to TRH; the distinction between blunted (pituitary) and preserved/delayed (hypothalamic) response is the test's clinical purpose, and these two patterns are reliably different in most patients.
Option E: Option E is incorrect because the TRH stimulation test for central hypothyroidism specifically monitors the TSH response (and secondarily the prolactin response, which confirms adequate TRH delivery); while TRH does stimulate prolactin and a prolactin response is observed, the primary diagnostic readout is the TSH rise, not the prolactin rise — prolactin measurement is confirmatory that TRH reached the pituitary, not the primary endpoint for diagnosing thyrotroph dysfunction.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.